INNOQUEST DIAGNOSTICS PTE. LTD.

The Ministry of Transport oversees the development and regulation of civil aviation, maritime, and land transport in Singapore. Our goal is to enhance national competitiveness and improve the quality of life through effective policies and efficient operations. We set policies and work with statutory boards such as CAAS, LTA, MPA, and PTC to implement and manage transport systems. Additionally, we supervise the Transport Safety Investigation Bureau.

Innoquest Diagnostics Pte Ltd, established in March 2021 through the merger of Quest Laboratories Pte Ltd and Innovative Diagnostics Pte Ltd, operates from seven facilities in Singapore. Our main laboratory features the Roche total laboratory automation system, capable of processing over 10,000 patient samples daily.

Since 2004, Innovative Diagnostics (ID) develops, produces and sells ELISA, PCR and rapid tests to diagnose infectious zoonotic and veterinary diseases. Over 130 employees work in our 4000 m² headquarters at the heart of the “MED Valley” of Montpellier, France. ID has shown continuous growth over the years and offers a wide range of veterinary tests sold in over 100 countries under the brand name IDvet. ID is an actor of the One Health approach, which recognizes that human and animal health are interdependent. We contribute to securing the global health and food supply, thanks to the control of zoonotic and veterinary diseases. Further to the emergence of COVID-19, we quickly developed COVID-19 ELISA tests detecting IgG, IgA and IgM in sera, and an immunochromatographic test for nasopharyngeal swabs. “With you at every step” is our motto. To improve global supply and assistance, we have a training center in Jordan, offices in Brazil, India, China, and a production facility in the USA. In 2016, we contributed to creating ID Solutions (www.id-solutions.fr) to provide tools to detect oncogenic mutations in human circulating DNA by dPCR. When COVID-19 emerged, ID made its know-how, industrial infrastructures, staff and financial resources available to ID Solutions in order to develop and produce COVID-19 PCR kits for use in humans, allowing ID Solutions to become a major COVID PCR kit manufacturer in France. ID left ID Solutions presidency in December 2021 and sold all its shares in May 2022. ID Solutions is now fully independent and heading for their new own projects. In 2021, ID contributed to the creation of DI4diag: “Deep Intelligence for diagnostics”. This company gathers talents from Montpellier University and the industry. It aims to provide easy-to-use and affordable diagnostics for syndromic infectious diseases, thanks to technologies that combine molecular technics and artificial intelligence. These testing tools will be particularly useful for LMIC.